Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Depreciation & Amortization (CF) (2019 - 2025)

Historic Depreciation & Amortization (CF) for Biodesix (BDSX) over the last 7 years, with Q3 2025 value amounting to $1.4 million.

  • Biodesix's Depreciation & Amortization (CF) fell 582.72% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.7 million, marking a year-over-year increase of 809.13%. This contributed to the annual value of $5.8 million for FY2024, which is 7346.75% up from last year.
  • Latest data reveals that Biodesix reported Depreciation & Amortization (CF) of $1.4 million as of Q3 2025, which was down 582.72% from $1.4 million recorded in Q2 2025.
  • In the past 5 years, Biodesix's Depreciation & Amortization (CF) ranged from a high of $1.5 million in Q3 2024 and a low of $746000.0 during Q1 2021
  • Its 5-year average for Depreciation & Amortization (CF) is $1.1 million, with a median of $898000.0 in 2022.
  • In the last 5 years, Biodesix's Depreciation & Amortization (CF) plummeted by 1354.63% in 2023 and then skyrocketed by 9092.07% in 2024.
  • Over the past 5 years, Biodesix's Depreciation & Amortization (CF) (Quarter) stood at $855000.0 in 2021, then increased by 5.03% to $898000.0 in 2022, then grew by 8.8% to $977000.0 in 2023, then soared by 48.31% to $1.4 million in 2024, then decreased by 2.97% to $1.4 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $1.4 million for Q3 2025, versus $1.4 million for Q2 2025 and $1.4 million for Q1 2025.